Signant Health Upgrades Clinical Supplies Management Platform
GxP Inventory available in two options for varying sponsor and CRO requirements.
Signant Health has relaunched its Signant SmartSignals Supplies GxP Inventory, an upgrade to its SmartSignals Supplies software. It available as either an Essential or Enterprise option, both of which are SaaS-based, with decisions revolving around company and/or trial size.
The Essential option enables sponsors to use a pre-configured system for inventory manufacturing, management, and QA/QP release. The Enterprise option provides advanced features for larger customers with internal supply chain capabilities to meet individualized requirements, sponsor-specific terminology/labels, and additional workflow/process options.
Reference: Signant Health Extends the Power of Clinical Supply Management Software to the Small and Mid-Size Market Through Updated and Enhanced Supplies Platform, Philadelphia, PA, July 10, 2023.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
VERITAC-2 Trial Shows Vepdegestrant Significantly Improves Survival in ESR1-Mutant Breast Cancer
March 24th 2025Phase III VERITAC-2 trial results show vepdegestrant significantly improved progression-free survivalcompared to fulvestrant in patients with ESR1-mutant (ESR1m) advanced or metastatic breast cancer, but did not achieve statistical significance in the overall intent-to-treat population.
